MA01.06 Phase 2 of Pro-Autophagic Drug ABTL0812 in Combination With First-Line Paclitaxel and Carboplatin in IIIb/IV Squamous NSCLC

ABTL0812 induces cytotoxic autophagy-mediated cancer cell death. It induces endoplasmic reticular (ER)-stress, and inhibits Akt/mTOR axis by upregulating TRIB3, an endogenous Akt inhibitor. Both actions, ER stress and blockade of Akt/mTOR, converge to induce a sustained and robust autophagy. Preclinical data in non-small cell lung carcinoma (NSCLC) indicated efficacy as a single agent and synergy with chemotherapy. A phase 1 of ABTL0812 in combination with paclitaxel and carboplatin (P/C) confirmed the safety of the triple combination